Extracorporeal SPecific IgE Removal From the Plasma of Allergic Asthma Patients (ESPIRA-study) (ESPIRA)

March 5, 2015 updated by: Fresenius Medical Care Deutschland GmbH

First in Man Trial to Investigate Safety and Efficacy of the New IgE Adsorber

In this study patients suffering from Immunoglobulin E (IgE) mediated asthma are treated with a method, called immune apheresis, that removes IgE from blood. In order to achieve this blood is taken continuously from the patient and then separated into plasma and blood cells by centrifuge. The plasma passes the new IgE adsorber where the IgE is specifically bound. The "cleaned" plasma re-joined with the blood cells is given back to the patient. In total each patient randomized to the apheresis group will undergo 3 treatments per week (i.e. 1 cycle) every 4 weeks over a time period of 3 months, that means 9 apheresis treatments in 3 cycles in total. Study hypothesis is that the new IgE adsorber is capable of reducing IgE in plasma/serum by at least 50% measured before the first treatment in the first cycle and after the last treatment in the last treatment cycle. The new adsorber can be safely used in patients. A group of patients with conventional drug treatment and no apheresis treatment serves as control.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Vienna, Austria, A-1090
        • Medical University Vienna

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Signed Informed Consent
  • Clinically relevant allergy to respiratory allergens confirmed by patient's history, skin-prick testing, IgE serology
  • Allergic asthma (diagnosed by lung specialist)
  • IgE concentration in blood at least 300 kilo Units (kU)/L

Exclusion Criteria:

  • Participation in another trial within 30 days prior to enrolment
  • Gravidity (pregnancy test prior to each treatment cycle)
  • Intake of omalizumab
  • Hepatitis or HIV or malignant disease
  • Specific immunotherapy in the last 6 months
  • Non-allergic asthma
  • Auto-immune diseases
  • Hypocalcaemia
  • Intake of ACE-inhibitors (discontinuation according to half-time before treatment possible)
  • Uncontrolled bleeding and coagulation disorders
  • Severe cardiovascular disease
  • Severe cardiac arrhythmias
  • Severe systemic infection
  • Unability to tolerate therapeutic apheresis procedures (hypersensitivity associated with previous apheresis sessions)
  • Inadequate peripheral venous access
  • Condition in which acute fluid shifts may cause congestive heart failure
  • Established or suspected intra-cranial disease where fluid imbalance or pressure changes could exacerbate the disease
  • Impaired renal function
  • Clinically significant hypotension or borderline hypotension where a further drop in blood pressure could be harmful

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: apheresis, IgE adsorber
9 apheresis treatments with the new IgE adsorber in a period of 3 months with 3 cycles of 3 treatments each every month.
Device: IgE adsorber
Two plasma volumes of each patient in the apheresis group will be treated per session
No Intervention: Conventional drug treatment
Patients treated with conventional asthma treatment as prescribed before study entry. No intervention in prescription

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction of IgE concentration in Plasma/Serum
Time Frame: Before first treatment (baseline) to after the last of 9 treatments over a time period of 3 months
Decrease in IgE concentrations from before the first apheresis treatment (in the control group the first blood sampling) to after the last apheresis treatment after three months (in the control group last blood sampling after three months)
Before first treatment (baseline) to after the last of 9 treatments over a time period of 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fresenius Medical Care Deutschland GmbH

Investigators

  • Principal Investigator: Kurt Derfler, Prof. Dr., Dep. of Internal Medicine III, Nephrology and Dialysis

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2013

Primary Completion (Actual)

July 1, 2014

Study Completion (Actual)

November 1, 2014

Study Registration Dates

First Submitted

March 21, 2014

First Submitted That Met QC Criteria

March 25, 2014

First Posted (Estimate)

March 26, 2014

Study Record Updates

Last Update Posted (Estimate)

March 6, 2015

Last Update Submitted That Met QC Criteria

March 5, 2015

Last Verified

March 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TA-IgE-01-A

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Allergic Asthma

Clinical Trials on IgE adsorber

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe